Researchers with the University North Texas have examined optimized curcumin [Longvida®] supplementation as therapy for Exercise-Induced Muscle Damage (EIMD) and Delayed Onset Muscle Soreness (DOMS) impact post training and Activities of Daily Living (ADL). The study was intended to determine the effects of 400mg/day of Longvida® Optimized Curcumin “on muscle and ADL soreness, creatine kinase (CK), and inflammatory cytokines (TNF-α, IL-6, IL-8, IL-10) following exercise-induced muscle damage .”
Twenty-eight participants were randomly assigned to either 400mg/day supplementation of Longvida® or placebo, then participated in a leg press exercise. Blood samples were taken before the exercise, and at one, two, three, and four days post exercise. These were used to measure and analyze creatine kinase (CK) and inflammatory cytokines, which were analyzed by ANOVA with p<0.05.
The study notates: “Curcumin supplementation resulted in significantly smaller increases in CK (-48%), TNF-α (-25%), and IL-8 (-21%) following EIMD compared to placebo. We observed no significant decreases in IL-6, IL-10, or quadriceps muscle soreness between conditions for this sample size.” Based on these results, a larger sample size should be examined to see if the trending lowering effect of these other markers could be significant.
Additionally, the findings indicated that the consumption of Longvida® Optimized Curcumin reduced inflammation, but not quadriceps muscle soreness during recovery post induction of exercise muscle soreness. Dr. McFarlin states, “The observed improvements in biological inflammation may translate to faster recovery and improved functional capacity during subsequent exercise sessions.”
In summary, researchers’ findings, “support the use of oral curcumin supplementation [as Longvida® Optimized Curcumin] to reduce the symptoms of EIMD.” ¹ Sonya Cropper, VP of Marketing & Innovation with Verdure Sciences, stated, “I am pleased to see additional support of Longvida’s efficacious capability to promote active lifestyle activities. It is impressive to see a second clinical that supports Longvida’s impact on particular biomarkers that influence health.” †
Patented Longvida® Optimized Curcumin was developed by Verdure Sciences® in collaboration with UCLA neuroscientists with over ten years of bioavailability, efficacy, and safety testing. Longvida®’s SLP™ Technology is able to reach target tissues offering efficacious levels of free curcumin at a low daily dose. Longvida® (US Patent 9192644, EP Patent 19933665; additional patents pending) is a registered trademark of Verdure Sciences®, Inc. SLP™ and SLCP™ are trademarks of Verdure® Sciences, Inc.
Visit Longvida.com for more information
About Verdure Sciences®
Verdure Sciences manages ingredient innovation throughout the integration of supply network, production, and research platforms. With an expanding pipeline of proprietary, standardized botanical ingredients supported by pharmacokinetic, pharmacodynamic, and clinical research profiles, we work toward our unified vision to offer safe, effective ingredient solutions. Verdure Sciences® is a registered trademark of Verdure Sciences®, Inc.
Visit VS-Corp.com for more information
¹McFarlin BK et al. Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin. BBA Clinical. 2016 February 17. DOI: 10.1016/j.bbacli.2016.02.003
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
For additional information: http://www.sciencedirect.com/science/article/pii/S2214647416300034